Accord UK has launched Dutasteride 0.5mg Soft Capsules, following a patent expiry. Dutasteride 0.5mg Soft Capsules are indicated in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) and reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.

Pete Kelly, managing director of Accord UK said: “We remain committed to bringing cost competitive products to market at the earliest opportunity, with the launch of Dutasteride 0.5mg Soft Capsules being our latest day one patent expiry launch.”

ACCORD UK 0800 731 0370, accordscheme.com

Recommended

Nytol campaign to boost confidence in use of sleeping aids

The aim of Nytol's new campaign is to help break down any reluctance in the use of sleeping aids

Deep relief shows off new branding on TV

Deep Relief, from The Mentholatum Company, is on TV for four weeks to the end of February with a fun creative featuring ...